Verona Pharma strengthens commercialization leadership team
Retrieved on:
Wednesday, August 24, 2022
Circassia Group, Salix Pharmaceuticals, Commercial, VRNA, Associate, Bachelor of Liberal Studies, Iowa State University, Degenerative disease, US Foods, Liberal arts education, Maintenance, New Drug Application, Chronic obstructive pulmonary disease, Head, Food, Senior, BLS, Pharmacy benefit management, Cystic fibrosis, Market access, GLOBE, Nasdaq, Company, Therapy, PBM, Abbott Laboratories, Business, Payment, Marketing, Laboratory, Acquisition, Communication, Pharmaceutical industry, Speech, West Chester University
LONDON and RALEIGH, N.C., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma or the Company), a clinical-stage biopharmaceutical company focused on respiratory diseases, continues its preparation for commercialization with appointments of Matthew Casbon, Vice President of Sales, Marketing and Training, and Matthew Rysavy, Vice President of Market Access and Trade.
Key Points:
- LONDON and RALEIGH, N.C., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (Verona Pharma or the Company), a clinical-stage biopharmaceutical company focused on respiratory diseases, continues its preparation for commercialization with appointments of Matthew Casbon, Vice President of Sales, Marketing and Training, and Matthew Rysavy, Vice President of Market Access and Trade.
- Chris Martin, Senior Vice President of Commercial, said: We are very pleased to welcome Mr. Casbon and Mr. Rysavy to Verona Pharma at this exciting time of Company growth and progression.
- Mr. Casbon brings over 25 years of commercial healthcare experience to Verona Pharma.
- Prior to Verona Pharma, Mr. Rysavy served as Head of Market Access and Trade at BioDelivery Sciences International, where he was responsible for building the Market Access team to support existing and launch products.